l

Ex situ determination of freely dissolved concentrations of hydrophobic organic chemicals in sediments and soils: basis for interpreting toxicity and assessing bioavailability, risks and remediation necessity




l

Simultaneous noninvasive recording of electrocardiogram and skin sympathetic nerve activity (neuECG)




l

Author Correction: Guidance for quantitative confocal microscopy




l

Cellular thermal shift assay for the identification of drug–target interactions in the <i>Plasmodium falciparum</i> proteome




l

Simultaneous quantification of protein–DNA interactions and transcriptomes in single cells with scDam&amp;T-seq




l

Nature Protocols




l

Tissue-specific alteration of gene expression and function by RU486 and the GeneSwitch system




l

Lifespan-increasing drug nordihydroguaiaretic acid inhibits p300 and activates autophagy




l

Daily blue-light exposure shortens lifespan and causes brain neurodegeneration in <i>Drosophila</i>




l

Short-term NAD<sup>+</sup> supplementation prevents hearing loss in mouse models of Cockayne syndrome




l

Repository of proposed pathways and protein–protein interaction networks in age-related macular degeneration




l

CMV-independent increase in CD27−CD28+ CD8+ EMRA T cells is inversely related to mortality in octogenarians




l

Organotypic human skin culture models constructed with senescent fibroblasts show hallmarks of skin aging




l

COVID-19 outcomes in patients with hematologic disease




l

High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission




l

Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome




l

Oral health in allogeneic hematopoietic stem cells transplantation survivors




l

Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody




l

Donor-derived DNA variability in fingernails of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation detected by direct PCR




l

Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment




l

Bone Marrow Transplantation




l

NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma




l

Irradiation induces cancer lung metastasis through activation of the cGAS–STING–CCL5 pathway in mesenchymal stromal cells




l

Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells




l

The HMGB1-RAGE axis modulates the growth of autophagy-deficient hepatic tumors




l

QKI deficiency leads to osteoporosis by promoting RANKL-induced osteoclastogenesis and disrupting bone metabolism




l

WTAP and BIRC3 are involved in the posttranscriptional mechanisms that impact on the expression and activity of the human lactonase PON2




l

LncRNA <i>SNORD3A</i> specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMPS expression




l

NF-kappa B interacting long noncoding RNA enhances the Warburg effect and angiogenesis and is associated with decreased survival of patients with gliomas




l

Cell Death & Disease




l

MicroRNA let-7c (MIRLET7C; let-7c), miR-99a and miR-125b as prognostic markers of luminal breast cancer

Studies in patient samples and cell culture suggest let-7c, miR-99a and miR-125b could serve as prognostic markers in patients with estrogen receptor–positive luminal breast cancers.




l

Chromosome 11 open reading frame 30 (C11orf30), calpain small subunit 1 (CAPNS1; CAPN4), signal transducer and activator of transcription 6 (STAT6) and ankyrin repeat domain 27 (ANKRD27) as diagnostic markers for eosinophilic esophagitis (EoE)

Genomewide association studies identified four genes that could serve as diagnostic markers and/or therapeutic targets for EoE.




l

Tumor-selective delivery of antisense oligomers (antimiRs) against oncogenic microRNAs

miRNA-targeted antimiRs conjugated to a peptide with a low pH–induced transmembrane structure (pHLIP) could help treat solid tumors.




l

RNAi against therapeutic targets with short interfering ribonucleic neutrals (siRNNs)

siRNNs could enable RNAi knockdown of therapeutic targets in a broader range of cells and tissue types than siRNA.




l

Extending therapeutic protein half-lives via fusion to affibodies with pH-dependent binding to neonatal Fc receptor

Fusing therapeutic proteins to affibodies with pH-dependent binding to neonatal Fc receptor could improve the proteins' half-lives.




l

Nanomolar-scale, high throughput chemical synthesis of drug-like molecules

A high throughput, miniaturized chemical synthesis platform could enable rapid discovery of lead compounds.




l

Influenza A virus hemagglutinin

Cell and mouse studies have identified pentacyclic triterpenoid analogs that could help treat influenza infections and have lower risk for resistance than amantadine.




l

Glutathione peroxidase 4 (GPX4)

Mouse studies suggest inhibiting ferroptosis could help treat ischemia/reperfusion injury in the liver and kidney.




l

Angiopoietin 2 (ANG2; ANGPT2); placental growth factor (PGF; PlGF); tissue inhibitor of metalloproteinases 3 (TIMP3)

Mouse studies suggest inhibiting PGF could help treat hypertension.




l

c-jun N-terminal kinase (JNK); MAP kinase 1 (MAPK1; ERK-2); MAPK3 (ERK-1)

In vitro and rodent studies suggest ophiopogonin D could help prevent doxorubicin-induced cardiotoxicity.




l

Sortilin 1 (SORT1)

Mouse studies suggest inhibiting SORT1 in macrophages and T cells could help treat atherosclerosis.




l

Globohexaosylceramide (globo-H); stage-specific embryonic antigen-3 (SSEA-3); SSEA-4

Mouse studies suggest chemically modified carbohydrate conjugates could be useful as antigens for the development of cancer vaccines.




l

Epidermal growth factor receptor 1 (EGFR1; ErbB1; HER1); HER2 (EGFR2; ErbB2; neu); HER3 (EGFR3; ErbB3); VEGF

Tumor cell and mouse studies suggest tetravalent antibodies that target four different antigens could help treat cancers resistant to HER-targeted therapies.




l

Cyclin dependent kinase 7 (CDK7); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC)

In vitro and mouse studies suggest THZ1, a covalent CDK7 inhibitor, could help treat neuroblastoma and other cancers driven by MYCN and other c-MYC (MYC)-family oncoproteins.




l

Estrogen receptor; LYN kinase (LYN); phosphoinositide 3-kinase (PI3K)

Studies in mice and human samples suggest inhibiting LYN could help treat estrogen receptor–positive breast cancers resistant to anti-estrogen therapy.




l

Genocea's mark on malaria

Genocea has identified an immunological imprint in patients with malaria and is using a $1.2 million grant from the Gates Foundation to turn the findings into a vaccine.




l

Resurrecting a magic bullet

Heidelberg Pharma has resuscitated a long-dead ADC toxin with updated conjugation techniques, and its partner Roche has thrown the company a lifeline that could help validate the platform.




l

Translational tidbits

Yabao and MRC Technology partner in PD; charities form Neuro-MAP to insource pharma's abandoned compounds; Singapore creates a diagnostic hub; a roundup of public-private partnerships.




l

Translational balance

Moving discoveries from academia to industry requires a delicate balance of risk, reward, skill sets and personalities, according to a translational panel held at BIO-Europe's partnering conference.




l

Neutralizing the negatives of RNAi

The siRNN technology that Solstice licensed from UCSD could take RNAi-based therapies to tissues outside the liver and expand their use to a host of new diseases.